Clinical Research Documentation That Gets Approved
ICH E3-compliant CSRs, protocols, investigator brochures, and regulatory submissions. Written by PhD-level medical writers with pharma and biotech experience. FDA · EMA · PMDA · SFDA.
Compliance
Standards
Formatting
SFDA Coverage
Starts
What Is Clinical Research Documentation?
Before any drug or medical device reaches patients, regulators like the FDA, EMA, and PMDA require a mountain of documentation proving it is safe and effective. Clinical research documentation is that mountain — and getting it wrong means delays, rejection, or costly re-submissions.
- CSR (Clinical Study Report): The single most important document in any regulatory submission. Follows ICH E3 guidelines — typically 200–500+ pages.
- Protocol: The study blueprint filed with regulators and ethics committees before a single patient is enrolled. Errors here cascade through the entire trial.
- IB (Investigator's Brochure): Everything investigators need to know about the drug — pharmacology, toxicology, prior clinical data. Updated throughout the trial lifecycle.
Quick Check: Which ICH guideline governs CSR structure and content?
Complete Clinical Documentation Services
12 regulatory document types covering every stage of drug development — from first-in-human to post-marketing. Each linked to ICH, FDA, and EMA requirements.
- CSR
Clinical Study Report
Comprehensive ICH E3-compliant CSR with integrated safety/efficacy analysis, statistical interpretation, and all appendices.
$50,000 USDView Details → - PROTOCOL
Clinical Protocol Development
Scientific protocol design aligned with regulatory expectations. Objectives, methodology, statistical considerations, and ethics committee readiness.
$28,000 USDView Details → - IB
Investigator's Brochure
Complete IB development: pharmacology, toxicology, prior clinical data, risk-benefit assessment. Updated throughout the trial lifecycle.
$25,000 USDView Details → - CTD
IND/CTA Module Development
CTD Modules 2.5 and 2.7 — clinical overview and clinical summary for IND/CTA submissions across FDA, EMA, and PMDA.
$35,000 USDView Details → - ISS/ISE
NDA/MAA Integrated Summaries
Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE) for NDA/MAA submissions. Cross-study data pooling and analysis.
$75,000 USDView Details → - PSUR
PSUR/PBRER Safety Reports
Periodic Safety Update Reports and Periodic Benefit-Risk Evaluation Reports for post-marketing safety monitoring and regulatory compliance.
$25,000 USDView Details → - RMP
EU Risk Management Plan
EU RMP development including safety specification, pharmacovigilance plan, and risk minimisation measures per EMA GVP Module V.
$18,000 USDView Details → - PIP
Pediatric Investigation Plan
PIP development for EMA submission including paediatric study design, age-appropriate formulation considerations, and waiver/deferral justification.
$12,000 USDView Details → - SYNOPSIS
Clinical Study Synopsis
Concise study synopsis for protocol registration, ethics committee submission, or ClinicalTrials.gov posting requirements.
$6,500 USDView Details → - ICF
Informed Consent Form
IRB/EC-ready informed consent documents written in plain language. Compliant with ICH E6(R2) GCP and local regulatory requirements.
$4,500 USDView Details → - AMEND
Protocol Amendment
Documented protocol amendments with rationale, change summary, and impact assessment for regulators and ethics committees.
$8,000 USDView Details → - NARRATIVE
Patient Narrative Development
Individual patient narratives for serious adverse events (SAEs), deaths, and significant protocol deviations per ICH E3 requirements.
$800 USD / narrativeView Details →
From Regulatory CSR to Published Manuscript
Most CROs stop at the CSR. We go further — turning your clinical data into peer-reviewed publications that build your research portfolio and attract citations.
Regulatory Documentation
We write your CSR, protocol, IB, and submission documents to ICH/GCP standards for FDA, EMA, or PMDA filing.
Journal Manuscript
We transform the same clinical data into a publication-ready manuscript targeting high-impact journals in your therapeutic area.
- Same PhD-level team writes both the CSR and the manuscript — zero knowledge loss
- Data consistency guaranteed between regulatory filing and publication
- Faster time-to-publication — no onboarding a second writing team
- Builds your H-index while meeting regulatory obligations
How We Work
A structured engagement model designed for regulatory timelines and sponsor oversight requirements.
Confidential Scoping Call
NDA signed upfront. We assess your trial phase, therapeutic area, regulatory targets (FDA/EMA/PMDA), and document scope. You receive a detailed proposal within 48 hours.
Document Planning & Shell Development
We build the document shell (CSR, protocol, or IB structure) aligned with ICH E3 or relevant guidelines. You review and approve before writing begins.
Data Integration & Drafting
Medical writers integrate clinical data, statistical outputs (TFLs), and safety narratives into the approved shell. Biostatistics team verifies all data interpretations.
Multi-Tier QC & Sponsor Review
Internal medical review, statistical QC, and editorial review before sponsor handoff. Sponsor comment incorporation with full audit trail.
Finalization & Submission Support
Final document delivered in submission-ready format (PDF/Word + eCTD-compatible if needed). Post-delivery support for regulatory queries and deficiency responses.
Why Sponsors Choose Editverse
Regulatory medical writing backed by PhD-level expertise, integrated biostatistics, and strict data confidentiality.
PhD-Level Medical Writers
Writers with doctoral degrees in pharmacology, clinical medicine, and biostatistics. Direct pharma and CRO experience across Phase I–IV trials.
Integrated Biostatistics
In-house statisticians using R, SAS, and STATA verify every data interpretation. TFL generation and SAP development included where needed.
NDA-First Confidentiality
NDA signed before any project data is shared. All files deleted on completion. Zero client identity disclosure — privacy policy.
Multi-Regional Expertise
Documentation formatted for FDA, EMA, PMDA, and NMPA submission requirements.
AI Fabrication Shield
100% human-written content. Every data point verified against source documents. No AI-generated text in regulatory submissions — period.
CSR → Manuscript Pipeline
Unique: we write both the CSR and the journal manuscript from the same data. Manuscript writing services integrated.
"Editverse delivered our Phase III CSR two weeks ahead of schedule. The quality was exceptional — our regulatory team had minimal comments, and the EMA accepted the submission without deficiency letters. We've since engaged them for the manuscript publication as well."
Editverse vs Enterprise CROs
Large CROs charge $150K+ and lock you into multi-year contracts. We deliver the same regulatory-grade quality with faster turnaround, transparent pricing, and the added bonus of manuscript publication.
| Feature | Editverse | Large CROs | Freelance Writers |
|---|---|---|---|
| ICH E3 CSR Compliance | ✓ Full | ✓ Full | Varies |
| Multi-Regional (FDA/EMA/PMDA) | ✓ Yes | ✓ Yes | ✗ Usually single |
| Integrated Biostatistics | ✓ In-house | ✓ In-house | ✗ No |
| CSR → Journal Manuscript | ✓ Same team | ✗ Not offered | ✗ Not offered |
| AI Fabrication Shield | ✓ 100% human | Increasingly AI-assisted | ✗ Unknown |
| NDA Before Start | ✓ Always | ✓ Standard | On request |
| Transparent Pricing | ✓ Published | ✗ Quote only | ✓ Published |
| Minimum Contract | ✓ Per project | ✗ Multi-year MSA | ✓ Per project |
| Turnaround (CSR) | 6–10 weeks post-DBL | 8–16 weeks post-DBL | Varies widely |
| Post-Delivery Support | ✓ Deficiency responses | Extra SOW | ✗ Rarely |
Comparison based on publicly available information. "Large CROs" represents typical enterprise-level contract research organisations.
Working in Taiwan?
Taiwan’s Human Subjects Research Act sets its own submission rules, including documented ethics-training hours for every named investigator before a protocol is accepted. Our Traditional Chinese IRB training-hours and submission checker returns the committee to file with, the hours still owed, which courses count, and the expected review turnaround. Full local service at Editverse Taiwan.
Frequently Asked Questions
A CSR is a comprehensive document that presents the complete results and analysis of a clinical trial. It follows ICH E3 guidelines and is required for regulatory submissions to agencies like the FDA, EMA, and PMDA. A typical CSR ranges from 200 to 500+ pages and includes efficacy analysis, safety data, statistical interpretation, and all supporting appendices.
We typically deliver the first draft CSR within 6–8 weeks after database lock (DBL), depending on trial complexity, number of sites, and volume of safety data. The full cycle including sponsor review, comment incorporation, and finalization is usually 10–14 weeks post-DBL. We can also develop the CSR shell before DBL to accelerate the timeline.
Yes. Our medical writers have experience preparing documentation for FDA (IND/NDA), EMA (CTA/MAA), PMDA, and NMPA (China). We address region-specific requirements including CTD module formatting, local language summaries, and agency-specific safety reporting standards.
Yes — this is one of our key differentiators. The same PhD-level team that writes your CSR can transform the clinical data into a publication-ready manuscript for a peer-reviewed journal. This ensures data consistency between the regulatory filing and the publication, eliminates the need to onboard a second team, and accelerates time-to-publication. See our manuscript writing services.
An NDA is signed before any project data is shared. All project files are stored on encrypted systems and permanently deleted upon project completion. We never disclose client identities, trial details, or compound information. Our privacy policy and NDA terms are available for review.
No. All regulatory documents are 100% human-written by our PhD-level medical writing team. We do not use AI-generated text in any regulatory submission document. Every data point is manually verified against source documents and statistical outputs. This is non-negotiable for regulatory documentation where data integrity is paramount.
Our team has experience across oncology, cardiology, neurology, endocrinology, immunology, infectious disease, rare diseases, dermatology, ophthalmology, and medical devices. For highly specialised therapeutic areas, we match your project with a writer who has direct experience in your indication.
We offer transparent, project-based pricing — no multi-year contracts required. Prices are published on our website: CSRs from $50,000, protocols from $28,000, IBs from $25,000, patient narratives from $800 each. Custom packages are available for multi-document engagements. View all services and pricing.
Start Your Regulatory Documentation Project
Confidential consultation with our medical writing team. NDA signed before any project details are shared. Proposal delivered within 48 hours.